• Wenqian Li, Rilan Bai, Hanfei Guo, and Jiuwei Cui.
• Department of Cancer Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, China.
• Chin. Med. J. 2023 Dec 5; 136 (23): 277627862776-2786.

AbstractEpidermal growth factor receptor ( EGFR ) mutations are common oncogenic driver mutations in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine kinase inhibitors (TKIs) is beneficial for patients with advanced and early-stage NSCLC. With the development of next-generation sequencing technology, numerous patients have been found to have more than one genetic mutation in addition to a single EGFR mutation; however, the efficacy of conventional EGFR-TKIs and the optimal treatments for such patients remain largely unknown. Thus, we review the incidence, prognosis, and current treatment regimens of EGFR compound mutations and EGFR concomitant mutations to provide treatment recommendations and guidance for patients with these mutations.Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

23 keywords...

hide…